PRRT plus holmium‐166‐SIRT (HEPAR PLuS) versus PRRT‐only in patients with metastatic neuroendocrine tumors: A propensity‐score matched analysis
Authors:
Open Access
- 29 April 2025
- journal article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (8) , e70034
Abstract
Patients with bulky neuroendocrine liver metastases (NELM) undergoing PRRT with [177Lu]Lu‐DOTATATE have a worse survival than patients with limited liver metastases. Previously, the safety and efficacy of additional selective internal radiotherapy (SIRT), using holmium‐166 (166Ho)‐microspheres, directly following PRRT in patients with NELM were confirmed in the prospective HEPAR PLuS study. The aim of the current study was to provide insight into the efficacy and survival benefit of PRRT + 166Ho‐SIRT over PRRT‐only by means of a propensity score matched historical cohort. A multicenter retrospective data collection was performed to match patients treated with PRRT‐only to the prospectively collected HEPAR PLuS study patients. Demographic, clinical, laboratory, and imaging data were collected. The primary endpoint was the proportion of patients with progression‐free survival (PFS) at 2 years after the start of PRRT. Secondary endpoints included the proportion of patients with 2‐year hepatic PFS (hPFS), general PFS and hPFS, objective response rates (ORR), and overall survival (OS). Twenty‐four patients were 1:1 matched and included in the analysis. All key matching criteria were balanced between cohorts if feasible. The proportion of patients with PFS and hPFS at 2 years was 68% and 82% after PRRT + 166Ho‐SIRT versus 55% and 50% after PRRT only. Time to median PFS was comparable (31 vs. 30 months). An initial delay in hepatic progression or death of any cause was observed in PRRT + 166Ho‐SIRT mNET patients (75% probability of PFS at 27 vs. 22 months), most notably in intestinal tumors (75% probability of PFS at 26 vs. 15 months). Best ORR was 71% after PRRT + 166Ho‐SIRT versus 25% after PRRT only. This study showed that 166Ho‐SIRT after PRRT (vs. PRRT‐only) had a positive effect on the liver disease progression in patients with NELM, increasing the 2‐year hPFS rate and tumor response and delaying hepatic progression or death. However, this effect did not translate into improving general PFS and OS.Keywords
Funding Information
- Terumo
This publication has 26 references indexed in Scilit:
- Dose–effect relationships in neuroendocrine tumour liver metastases treated with [166Ho]-radioembolizationEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Integrated Capecitabine–Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective StudyCardioVascular and Interventional Radiology, 2023
- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysisHPB, 2019
- Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and ToxicityCardioVascular and Interventional Radiology, 2019
- Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver MetastasesJournal of Vascular and Interventional Radiology, 2018
- Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the LiverJournal of Vascular and Interventional Radiology, 2017
- Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall SurvivalCardioVascular and Interventional Radiology, 2016